Evidence map›Paper›PMID 36157937›Full record

ReviewWorld journal of gastroenterology2022

Liver regeneration as treatment target for severe alcoholic hepatitis.

Lucija Virovic-Jukic, Dominik Ljubas, Sanja Stojsavljevic-Shapeski, Neven Ljubičić, Tajana Filipec Kanizaj, Ivana Mikolasevic, Ivica Grgurevic

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Serum HMGB1 and Alcohol-Related Liver Disease.Journal of clinical medicine · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucija Virovic-JukicDepartment of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb 10000, Croatia.
Dominik LjubasDepartment of Internal Medicine, University of Zagreb School of Medicine, Zagreb 10000, Croatia.
Sanja Stojsavljevic-ShapeskiDepartment of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb 10000, Croatia.
Neven LjubičićDepartment of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb 10000, Croatia.
Tajana Filipec KanizajDepartment of Internal Medicine, University of Zagreb School of Medicine, Zagreb 10000, Croatia.
Ivana MikolasevicDepartment of Gastroenterology, Rijeka University Hospital Center, Rijeka 51000, Croatia.
Ivica GrgurevicDepartment of Internal Medicine, University of Zagreb School of Medicine, Zagreb 10000, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe alcoholic hepatitis (AH) is a distinct entity in the spectrum of alcohol-related liver disease, with limited treatment options and high mortality. Supportive medical care with corticosteroids in selected patients is the only currently available treatment option, often with poor outcomes. Based on the insights into the pathogenetic mechanisms of AH, which are mostly obtained from animal studies, several new treatment options are being explored. Studies have implicated impaired and deranged liver regeneration processes as one of the culprit mechanisms and a potential therapeutic target. Acknowledging evidence for the beneficial effects of granulocyte colony-stimulating factor (G-CSF) on liver regeneration and immunomodulation in animal models, several human studies investigated its role in the treatment of advanced alcohol-related liver disease and AH. Contrary to the previously published studies suggesting benefits of G-CSF in the outcomes of patients with severe AH, these effects were not confirmed by a recently published multicenter randomized trial, suggesting that other options should rather be pursued. Stem cell transplantation represents another option for improving liver regeneration, but evidence for its efficacy in patients with severe AH and advanced alcohol-related liver disease is still very scarce and unconvincing, with established lack of efficacy in patients with compensated cirrhosis. In this review, we summarize the current knowledge on the pathogenesis and experimental therapies targeting liver regeneration. The lack of high-quality studies and evidence is a major obstacle in further treatment development. New insights into the pathogenesis of not only liver injury, but also liver regeneration processes are mandatory for the development of new treatment options. A reliable experimental model of the pathogenesis of AH and processes involved in liver recovery is still missing, and data obtained from animal studies are essential for future research.

Indexed as

Focal Nodular HyperplasiaHepatitis, AlcoholicLiver DiseasesAdrenal Cortex HormonesAnimalsGranulocyte Colony-Stimulating FactorHumansLiver RegenerationAdrenal Cortex HormonesGranulocyte Colony-Stimulating FactorAlcohol-related liver diseaseGranulocyte colony-stimulating factorLiver regenerationSevere alcoholic hepatitisStem cell transplantationTreatment

Identifiers

PMID36157937
PMCPMC9476880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.